Ropes & Gray represented the underwriters in Bicara Therapeutics’ $150 million follow-on offering of shares of its common stock. The transaction priced on Feb. 24 and closed on Feb. 26.
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company intends to use the net proceeds of the offering to further invest in and build its medical and commercial infrastructure to support a planned regulatory filing and commercial launch for ficerafusp alfa, a first-in-class bifunctional antibody designed to treat multiple solid tumor cancers.
The team was led by capital markets partner Tom Danielski and counsel Elise Corey, life sciences regulatory & compliance partner Josh Oyster, and IP transactions partner Melissa Rones.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.